Murine colitis treated with multitargeted tyrosine kinase inhibitors
- 1 February 2016
- journal article
- research article
- Published by Elsevier in Journal of Surgical Research
- Vol. 200 (2) , 501-507
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Infliximab Therapy Inhibits Inflammation-Induced Angiogenesis in the Mucosa of Patients With Crohn's DiseaseAmerican Journal of Gastroenterology, 2011
- Neutralizing Anti-Vascular Endothelial Growth Factor (VEGF) Antibody Reduces Severity of Experimental Ulcerative Colitis in Rats: Direct Evidence for the Pathogenic Role of VEGFThe Journal of Pharmacology and Experimental Therapeutics, 2009
- VEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease PathogenesisGastroenterology, 2009
- Differential Angiogenic Regulation of Experimental ColitisThe American Journal of Pathology, 2006
- Angiogenesis as a Novel Component of Inflammatory Bowel Disease PathogenesisGastroenterology, 2006
- Angiogenesis as a therapeutic targetNature, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Angiogenesis in cancer and other diseasesNature, 2000
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995